A detailed history of China Universal Asset Management Co., Ltd. transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 12,422 shares of KYMR stock, worth $570,790. This represents 0.07% of its overall portfolio holdings.

Number of Shares
12,422
Previous 7,208 72.34%
Holding current value
$570,790
Previous $215,000 173.02%
% of portfolio
0.07%
Previous 0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$30.16 - $52.4 $157,254 - $273,213
5,214 Added 72.34%
12,422 $587,000
Q2 2024

Jul 19, 2024

SELL
$29.85 - $39.42 $135,668 - $179,163
-4,545 Reduced 38.67%
7,208 $215,000
Q1 2024

Apr 29, 2024

BUY
$22.9 - $43.57 $122,056 - $232,228
5,330 Added 82.98%
11,753 $472,000
Q4 2023

May 21, 2024

SELL
$10.97 - $26.84 $58,470 - $143,057
-5,330 Reduced 45.35%
6,423 $163,000
Q4 2023

Jan 23, 2024

BUY
$10.97 - $26.84 $54,871 - $134,253
5,002 Added 352.01%
6,423 $164,000
Q3 2023

May 21, 2024

BUY
$13.9 - $23.88 $9,674 - $16,620
696 Added 96.0%
1,421 $19,000
Q3 2023

Oct 30, 2023

BUY
$13.9 - $23.88 $9,674 - $16,620
696 Added 96.0%
1,421 $20,000
Q2 2023

May 21, 2024

SELL
$22.4 - $34.92 $515 - $803
-23 Reduced 3.07%
725 $16,000
Q2 2023

Jul 27, 2023

SELL
$22.4 - $34.92 $515 - $803
-23 Reduced 3.07%
725 $17,000
Q1 2023

May 21, 2024

BUY
$24.84 - $38.75 $4,744 - $7,401
191 Added 34.29%
748 $22,000
Q1 2023

Apr 27, 2023

BUY
$24.84 - $38.75 $4,744 - $7,401
191 Added 34.29%
748 $22,000
Q4 2022

May 21, 2024

SELL
$19.57 - $30.92 $219,105 - $346,180
-11,196 Reduced 95.26%
557 $13,000
Q4 2022

Jan 31, 2023

BUY
$19.57 - $30.92 $1,409 - $2,226
72 Added 14.85%
557 $14,000
Q3 2022

Oct 21, 2022

BUY
$20.91 - $34.27 $10,141 - $16,620
485 New
485 $11,000

Others Institutions Holding KYMR

About Kymera Therapeutics, Inc.


  • Ticker KYMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,705,800
  • Market Cap $2.51B
  • Description
  • Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...
More about KYMR
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.